DYN
NASDAQ HealthcareDyne Therapeutics, Inc. - Common Stock
Biotechnology
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
๐ Market Data
| Price | $16.22 |
|---|---|
| Volume | 498,392 |
| Market Cap | 3.04B |
| Beta | 1.080 |
| RSI (14-Day) | 10.0 Oversold |
| 200-Day MA | $19.74 |
| 50-Day MA | $23.56 |
| 52-Week High | $27.30 |
| 52-Week Low | $11.92 |
| Forward P/E | -4.88 |
| Price / Book | 3.84 |
๐ฏ Investment Strategy Scores
DYN scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (92/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Over-Hyped (2/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find DYN in your text
Paste any article, transcript, or post โ the tool will extract DYN and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-09-24.